athenahealth price target lowered to $90 from $120 at Oppenheimer Oppenheimer reduced its price target on athenahealth after the stock dropped following David Einhorn's pessimistic presentation about it. Oppenheimer believes that the company's margins are "structurally disadvantaged" versus those of pure software as a service companies. The firm keeps an Underperform rating on the stock.
athenahealth says targeting long-term adjusted gross margin in mid to high 70s Says targeting long-term adjusted operating margin in low to mid 30s. Comments from slides that are being presented at the JP Morgan Healthcare Conference.